tiprankstipranks
Trending News
More News >
Standard BioTools (LAB)
NASDAQ:LAB

Standard BioTools (LAB) AI Stock Analysis

Compare
452 Followers

Top Page

LA

Standard BioTools

(NASDAQ:LAB)

Rating:56Neutral
Price Target:
$1.50
▲(26.05%Upside)
Standard BioTools has a challenging financial position with significant leverage and ongoing losses, negatively impacting its overall score. However, recent corporate actions and strategic initiatives in proteomics offer potential for future growth. Technical analysis shows some positive short-term trends, but the valuation remains a concern due to persistent losses.
Positive Factors
Future Prospects
Signs of improvement on the horizon with positive customer trends, strengthening sales funnel, and momentum with SomaScan.
Operational Improvements
Solid operational expense controls showcase operational improvement despite a miss in gross margin due to mix and volume.
Revenue Performance
LAB reported 1Q revenue slightly better than consensus estimates, which is a good result in light of ongoing macro pressures and share weakness.
Negative Factors
Key Personnel Changes
The CFO departure (personal reasons) is a negative surprise though management is steadfast that key drivers (synergies, ILMN partnership) are unchanged.
Revenue Guidance
Disappointing initial 2025 revenue guidance of $165M-$175M vs. consensus of $186.9M, attributed to the proposed White House NIH spending cut.
Spending Environment
With a tepid spending environment and more meaningful commercial revenue from Illumina unlikely to occur until 2026, a downgrade to Sector Weight was issued.

Standard BioTools (LAB) vs. SPDR S&P 500 ETF (SPY)

Standard BioTools Business Overview & Revenue Model

Company DescriptionStandard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
How the Company Makes MoneyStandard BioTools generates revenue primarily through the sale of its instruments and related consumables. The company's revenue model is based on a combination of one-time sales of its advanced systems and recurring sales of consumables and reagents required for ongoing experiments. Additionally, they offer software solutions that complement their hardware, creating opportunities for additional revenue streams. Key partnerships with academic institutions, research organizations, and pharmaceutical companies enhance their market reach and contribute to their earnings. Service contracts and maintenance agreements also provide a stable, recurring income source.

Standard BioTools Earnings Call Summary

Earnings Call Date:May 06, 2025
(Q1-2025)
|
% Change Since: 12.26%|
Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment Neutral
The earnings call presented a mixed outlook. While the company showed strong financial discipline and growth in instrument sales, it faced notable revenue declines and challenges in the Americas academic market. Strategic initiatives in proteomics and partnerships offer promising future prospects but are yet to significantly offset current revenue challenges.
Q1-2025 Updates
Positive Updates
Positive Financial Improvements
Non-GAAP operating expenses decreased by 22% year-over-year, operating loss improved by 45%, and adjusted EBITDA improved by 29%. Cash burn reduced by 33% compared to the previous year.
Strategic Foothold in Proteomics
The company announced new SomaScan offerings and partnerships, particularly with Illumina, expanding their reach in clinical research. New product launches and strategic initiatives are driving interest and growth.
Strong Instrument Revenue Growth
Instrument revenue increased by 24% year-over-year, driven by demand for Hyperion XTi spatial imaging systems.
Negative Updates
Revenue Decline
Overall revenue for Q1 2025 was $40.8 million, down 10% year-over-year, with consumables revenue down 16% and services revenue down 16%.
Challenges in Americas Academia
A mid-teens percentage decline in Americas academic revenue is expected, with significant impacts on consumables and service revenue due to funding uncertainties.
Tariff Impacts
New tariff measures have added complexity and potential cost impacts, with some products now subject to a 10% tariff.
Company Guidance
In the first quarter of 2025, Standard BioTools reported revenue of $40.8 million, a 10% decline year-over-year, but in line with expectations. Despite challenges, including a dynamic operating environment and pressures from tariffs and funding, the company maintained its full-year revenue guidance of $165 million to $175 million. The revenue mix comprised 35% consumables, 19% instruments, and 43% services, with instruments showing double-digit growth driven by demand for the Hyperion XTi spatial imaging systems. The company also reported a 22% year-over-year improvement in non-GAAP operating expenses, with adjusted EBITDA improving by 29%. With $261 million in cash and equivalents and no material debt, Standard BioTools remains focused on managing costs and driving operational efficiencies, with an eye on achieving adjusted EBITDA profitability by 2026.

Standard BioTools Financial Statement Overview

Summary
Standard BioTools faces significant financial challenges, with persistent losses impacting profitability and cash flow. While the balance sheet is moderately stable due to a strong equity position, high leverage and negative cash flows pose risks. The company needs to address operational inefficiencies and improve revenue growth to achieve financial stability.
Income Statement
45
Neutral
The company's income statement shows significant challenges with profitability. The TTM data reveals a negative net profit margin and declining revenue, indicating persistent losses. The gross profit margin is relatively stable but overshadowed by high operating losses, reflected in negative EBIT and EBITDA margins. Revenue growth is inconsistent, with recent periods showing a decline. These factors suggest difficulties in scaling operations profitably.
Balance Sheet
60
Neutral
The balance sheet reflects a strong equity position with a positive equity ratio, but the company is highly leveraged, indicated by a significant debt-to-equity ratio. The return on equity is negative due to consistent net losses. However, cash reserves are healthy, partially offsetting the risks from high leverage. The overall balance sheet stability is moderate, with some financial risks due to the dependency on debt.
Cash Flow
50
Neutral
The cash flow statement shows negative operating and free cash flows, indicating cash burn and potential liquidity issues. However, there is a notable improvement in cash flow from financing activities, bolstering cash reserves. The company struggles with converting revenue to cash, as seen in low ratios of cash flow to net income. The trajectory of cash flows suggests efficiency improvements are necessary to achieve sustainability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue169.69M174.43M106.34M97.95M130.58M138.14M
Gross Profit79.81M84.26M50.45M37.05M69.37M83.33M
EBITDA-116.89M-118.14M-54.46M-173.57M-43.77M-34.60M
Net Income-132.76M-138.88M-74.66M-190.10M-59.24M-53.02M
Balance Sheet
Total Assets579.60M612.34M323.07M390.31M275.21M324.76M
Cash, Cash Equivalents and Short-Term Investments258.06M292.87M114.89M165.78M28.45M68.52M
Total Debt31.53M33.00M98.21M102.66M111.65M95.38M
Total Liabilities125.00M140.62M159.87M471.78M180.62M185.71M
Stockholders Equity454.60M471.72M163.20M-81.47M94.60M139.05M
Cash Flow
Free Cash Flow-123.89M-151.81M-46.12M-93.19M-57.33M-28.13M
Operating Cash Flow-111.26M-143.45M-43.29M-89.37M-44.06M-15.42M
Investing Cash Flow59.72M363.17M20.24M-88.13M-11.95M39.98M
Financing Cash Flow-82.93M-102.62M-6.81M230.76M15.96M20.86M

Standard BioTools Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.19
Price Trends
50DMA
1.11
Positive
100DMA
1.15
Positive
200DMA
1.50
Negative
Market Momentum
MACD
0.04
Negative
RSI
55.79
Neutral
STOCH
38.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LAB, the sentiment is Positive. The current price of 1.19 is above the 20-day moving average (MA) of 1.10, above the 50-day MA of 1.11, and below the 200-day MA of 1.50, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 55.79 is Neutral, neither overbought nor oversold. The STOCH value of 38.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LAB.

Standard BioTools Risk Analysis

Standard BioTools disclosed 53 risk factors in its most recent earnings report. Standard BioTools reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Standard BioTools Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
$587.55M30.59-1.20%38.43%86.19%
LALAB
56
Neutral
$451.99M-25.73%33.86%64.34%
55
Neutral
$581.18M-51.25%15.57%31.82%
OPOPK
52
Neutral
$1.05B-3.04%-13.79%82.82%
51
Neutral
$599.13M-3.61%1.71%76.00%
46
Neutral
C$190.36M-4.25-8.56%3.09%13.53%-1.76%
45
Neutral
$483.93M-13.84%7.38%60.45%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
LAB
Standard BioTools
1.19
-0.54
-31.21%
MYGN
Myriad Genetics
5.25
-18.72
-78.10%
OPK
Opko Health
1.32
0.09
7.32%
FLGT
Fulgent Genetics
19.68
-0.36
-1.80%
PSNL
Personalis
6.58
5.38
448.33%
CSTL
Castle Biosciences
20.35
-0.84
-3.96%

Standard BioTools Corporate Events

M&A TransactionsBusiness Operations and Strategy
Standard BioTools Sells Subsidiaries to Illumina
Positive
Jun 23, 2025

On June 22, 2025, Standard BioTools Inc. announced a strategic sale of its subsidiaries, including SomaLogic, to Illumina, Inc. for up to $425 million. This transaction aims to simplify Standard BioTools’ operations, achieve adjusted EBITDA break-even, and retain strategic upside through royalties and commercialization rights. The deal reflects improvements made to the business and aligns with the company’s focus on profitability and long-term value creation.

The most recent analyst rating on (LAB) stock is a Buy with a $2.75 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.

Executive/Board ChangesShareholder Meetings
Standard BioTools Approves Equity Plan Amendment at Meeting
Neutral
Jun 20, 2025

Standard BioTools Inc. held its 2025 Annual Meeting of Stockholders on June 18, 2025, where stockholders approved an amendment to the company’s Amended and Restated 2011 Equity Incentive Plan, increasing the number of shares of common stock reserved for issuance by 17,400,000 shares. Additionally, the election of Class III directors, approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm were also confirmed during the meeting.

The most recent analyst rating on (LAB) stock is a Buy with a $3.50 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.

Product-Related AnnouncementsBusiness Operations and StrategyFinancial Disclosures
Standard BioTools Q1 2025 Financial Results Overview
Neutral
May 6, 2025

Standard BioTools reported its financial results for the first quarter of 2025, showing a revenue of $40.8 million, a 10% decrease from the previous year. Despite the revenue decline, the company achieved a 45% reduction in operating loss and a 29% improvement in adjusted EBITDA, attributed to cost reductions and productivity gains. The company maintains a strong balance sheet with $261 million in cash and no material debt. The strategic focus on proteomics and the upcoming launch of a new NGS-based product are expected to drive future growth.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 24, 2025